Latest Regulatory News

Paradigm Biopharmaceuticals has strengthened its balance sheet with a combined $5.75 million cash inflow from Australian Government R&D tax incentives, supporting its pivotal Phase 3 osteoarthritis trial and regulatory efforts.

Union Star Metals has agreed to sell its Brazilian rare earth subsidiary to Harvest Minerals, receiving cash, shares, and milestone payments while sharpening its focus on gold and silver exploration in the US.

SkyCity Entertainment Group has signed a non-binding heads of agreement to sell The Grand Hotel, aiming to boost financial flexibility through asset monetisation and debt repayment.

Babylon Pump & Power has initiated a $12.7 million rights issue at a 37.5% discount to restore working capital, reduce debt, and expand its water management rental fleet, aiming to lift its ASX trading suspension.

The Takeovers Panel has received an application alleging undisclosed associations and possible breaches of takeover laws following a massive off-market transfer of Adslot shares valued at $723,870.

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.

CONNEQT Health's June quarter saw record consumer revenue growth and a 70% jump in enterprise subscription ARR, supported by a $5.5 million placement and progress on its FDA regulatory pathway for its cloud-based vascular analytics platform.

Triangle Energy (ASX:TEG) and its key subsidiaries have appointed a voluntary administrator amid financial pressures linked to offshore decommissioning obligations. The move follows similar steps by related operators and signals ongoing regulatory and creditor negotiations ahead.

Recce Pharmaceuticals secured a non-binding term sheet with a major Middle Eastern pharma for its diabetic foot infection treatment and raised A$4 million to fund pivotal Phase 3 trials in Australia and Indonesia.

Flagship Minerals has received full payment of US$4 million for its RK Lithium Project sale, advancing its strategic pivot towards gold and copper assets in Chile and Canada.

Biotron has received pivotal regulatory feedback from the European Medicines Agency ruling out a Hybrid Marketing Authorisation for SedRx, prompting plans for pivotal clinical trials. The company also advances its lead antiviral candidate BIT-HBV001 against Hepatitis Delta Virus and appoints a new chairman.

Silver Mines has confirmed robust economics for its Bowdens Silver Project, boosting ore reserves to 93.5 million ounces and outlining a 26-year mine life with a $455 million capital cost estimate.